PhI fiz­zle forces Sy­ros to spike its lead drug, trig­ger­ing an­oth­er rout on shares

Less than stel­lar Phase I re­sults have trig­gered a pipeline cleanup at Sy­ros Phar­ma, where one of its two lead drugs — a CDK7 in­hibitor ad­min­is­tered in­tra­venous­ly — is get­ting swapped out with an oral ver­sion.

The biotech said it main­tains its be­lief in the CDK7 path­way for can­cer, but thinks pri­or­i­tiz­ing SY-5609, which ap­pears more se­lec­tive and po­tent in pre­clin­i­cal mod­els, is a wis­er choice than hold­ing on­to an IV drug that didn’t quite em­body the op­ti­mal bal­ance be­tween ef­fi­ca­cy and tol­er­a­bil­i­ty. A hu­man tri­al for SY-5609 is planned for ear­ly next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.